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Oral Presentations S1711) At least one 8/8 HR matched donor exists on BTMR
2) No potential 8/8 HR donors exist
3) Potential 8/8 HR donors exist
PP searches falling into category 3 (accrued untilN5 200 per race)
then had anHLA search strategy expert rank potential donors within
BTMRinorder of theirmatching likelihood.Previously storeddonor
sampleswereHRHLA tested in order of ranking and evaluated to de-
termine match status. Consecutive rounds of donor sample testing
were performed until either an 8/8 matched donor was identified or
no potential donors with stored samples remained.
Results: The table below shows the 8/8 HRmatch rate of cases to be
68% for CAU, 42% forHIS, 45% for API, and 27% for AFA. Careful
review of the cases ‘‘Pending further testing; no stored sample’’ sug-
gests that few additional cases would yield 8/8 HR matches.
CAU PP HIS PP API PP AFA PP8/8 HR Matched 258 (68%) 128 (42%) 122 (45%) 105 (27%)
Pending Further Testing;
No Stored Sample
48 (13%) 65 (21%) 57 (21%) 54 (14%)No 8/8 HR Match 71 (19%) 114 (37%) 91 (34%) 231 (59%)
TOTAL 377 307 270 390Conclusions:This studyprovides a true8/8HRmatchrateestimate for
CAU,HIS, API, and AFA patients through BTMR, which has not been
accomplished previously. These results demonstrate the racial disparity
in HLA match rates and can be used to inform patients searching
BTMR.This studyalsoprovides vital information fordonor recruitment
and availability efforts. Results provide a baseline match rate that can be
further supplemented using the additional worldwide URD inventory.
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POIETIC STEM CELL TRANSPLANATION (HSCT): REPORT OF A PHASE II
TRIAL WITH 18 MONTHS OF FOLLOW-UP FOR ALL PATIENTS
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Haploidentical HSCT using post transplant cyclophosphamide
(CY) for elimination of alloreactive lymphocytes has been reported
as a safe option for patients lacking an HLA identical donor. We re-
port an alternate approachwith the following salient differences: mye-
loablative vs non-myeloablative conditioning, peripheral blood rather
than marrow stem cell source, no exposure vs exposure of HSC to cy-
clophosphamide, higher fixed number of CD3 cells versus a lower var-
iable number of CD3 cells in each graft. Results are reported nowwith
a followed up of 18-46 months.
Table 1. Patient Characteristics-2 Step ApproachAge 52 (19-67)AML 16Remission 7Resistant/PIF 9Biphenotypic Leukemia
(Active Disease)1ALL 4CR2 (ph-) 3Persistent Disease (PH+) 1MDS 2NHL Resistant 3SAA 1HLA MM (GVH Direction)4 133 112 20 1Patients received 12 Gy of total body irradiation (TBI), followed by
a donor lymphocyte product (DLI) containing 2  10e8 CD31
cells/kg (Step 1). This large dose of haploidentical lymphocytes re-
sulted in fever (median temperature 103.8f), diarrhea and rash. CY
60 mg/kg was given on days -3 and -2 resulting in resolution of symp-
toms. Tacrolimus and MMF were begun on day-1. A CD 34 selected
donor product was infused on day 0 (Step 2). Two of the 27 patients
died of toxicity and infection before day 14. Of the remaining 25 pa-
tients, 23 had complete engraftment while two with pre-existing
anti-donor HLA antibodies failed to engraft. Only 2 of 25 (8%) pa-
tients developed severe acuteGVHD, 3 of 25 (12%) developed limited
chronic GVHD, and no patient died of GVHD. Only two of 25 pa-
tients (8%) died of infection. Of 16 disease-free patients surviving 6
months from HSCT, median CD41 count at day 100 was 105 cells/
ml (range 10-403). Eight of 25 (32%) patients relapsed after HSCT.
Probability of survival (OS) at 1 and 3 years post transplant is 52%
and 48% respectively. All surviving patients are disease-free. OS at 3
years is 75% for patients transplanted inCR, but only 27% for patients
transplanted with active disease. KIR mismatching was not correlated
with relapse rates. In contrast, child tomother transplants for AMLap-
pear to be relapsing at higher rates than other combinations (66% vs
14%). In the context of CY tolerization, a dose of 2 10e8/kg T-cells
resulted inconsistent engraftment, prompt immune reconstitution, lit-
tle severe GVHD, acceptable toxicity, and encouraging overall sur-
vival, particularly in patients transplanted in CR. Using this 2-step
platform allows us to explore the use of alternate agents for the elimi-
nationof alloreactive lymphocytes, increase the lengthof time between
DLI andCY, and to employ twodonor strategies to improveoutcomes
in high risk patients.
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UNMANIPULATED HAPLOIDENTICAL STEM CELL TRANSPLANTATION
USING MYELOABLATIVE OR REDUCED-INTENSITY PRECONDITIONING
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Fujioka, T., Tamaki, H., Okada,M., Soma, T., Taniguchi, Y., Ogawa,H.
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Background: Related haploidentical donors, as cord blood, can be
alternative donor sources in stem cell transplantation (SCT). Severe
GVHD, however, has interfered the progress of haploidentical SCT
(haploSCT). To deal with this strong GVHD, T cell depletion has
usually been used in US and European countries. In order to pursue
the controllable GVL effect by T cells, we have performed unmanip-
ulated haploSCTusingmyeloablative or reduced intensity precondi-
tioning regimen accompanied with intensified GVHD prophylaxis.
In this meeting, we will summarize our experience of haploSCT
for more than ten years.
Patients: From August 1998 to September 2010, we have performed
351 cases of haploSCT (all cases were HLA 2-3 antigen mismatched
in GVH direction). Patients’ characteristics are sex: male 186, female
168, age: 16-65 years old (median 39), disease: AML/MDS 149, ALL
81, ML 67, others 54. 83% of cases underwent SCT in non-complete
remission (non-CR) state. Patients under 45 years old underwentmye-
loablative preconditioning regimen consisting of FLU/CA/CY/
TBI8Gy (haplo-full, n 5 100), and patients over 45 years old or
with comorbidities or repetitive SCT (including second to fifth
SCT) underwent reduced intensity preconditioning regimen consist-
ing of FLU/(CA)/BU/ATGor FLU/(CA)/MEL/ATG (haplo-mini, n
5 251). High dose Ara-C (CA) was optional to reduce tumor burden.
As ATG, ATG (Fresenius) 8mg/kg, or thymoglubulin (genzyme) 2-
4mg/kg were used. GVHD prophylaxis consisted of taclolimus
(TAC), methylprednisolone (mPSL) 2mg/kg/day, short term MTX,
and mycophenolate mofetil (MMF) 15mg/kg/day in haplo-full, and
TAC, mPSL 1mg/kg/day in haplo-mini, respectively. For elderly pa-
tients over 50 years old in haplo-mini, MMF was added.
Results: Hematopoietic engraftment in haploSCT was as rapid as
that in HLA-identical SCT, except ten cases of graft rejection. Acute
GVHD (grade II-IV) was observed in 30%. Overall survival in five
years is 30% in haplo-full and 40% in haplo-mini, respectively. If
limited to CR cases, overall survival reached over 60% in haplo-
mini. There is no difference in survival rate among patients’ diseases.
Discussion: Unmanipulated haploSCT is feasible and effective for
refractory diseases. ATG dose used in haplo-mini is critical, and
rather low compared with that of European cases reported so far.
S172 Oral PresentationsAlthough it should be too early to refer long term outcome, unma-
nipulated haploSCT could be considered as an option to fight
against refractory diseases.
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DONOR DAY 7 CD3 CHIMERISM IS PREDICTIVE OF THE LONG-TERM
ENGRAFTING UNIT FOLLOWING MYELOABLATIVE DOUBLE CORD
BLOOD TRANSPLANTATION (dCBT)
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Background: After myeloablative dCBT, one unit typically persists
as the engrafting unit responsible for long-term hematopoiesis. It has
been postulated that unit-versus-unit immune interactions contrib-
ute to the emergence of single donor dominance; however, there is
currently no reliable method of determining the winning unit. We
evaluated the role of donor day 7 CD3 peripheral blood (PB) chime-
risms on predicting the engrafting unit.
Methods: In this prospective single-center analysis, PB was flow
sorted into cell fractions, and DNA chimerism analysis was
performed by amplified fragment length polymorphism. Chimerism
detection sensitivity was 1-5%, with a range of accuracy 1/- 5%. A
logistic regression model was used to determine the correlation be-
tween a higher CD3 chimerism and the likelihood of being the pre-
dominant unit, and a t-test was applied to compare the mean CD3
chimerism of the winning versus losing unit.
Results: Between 10/2007-7/2010, 29 patients aged 12-63 years un-
derwent myeloablative dCBT for AML (n5 14), ALL (n5 8), CML
(n 5 2), MDS/MPD (n 5 4), and CLL (n 5 1). 17 patients received
13.2 Gy TBI, 120 mg/kg cytoxan, and 75 mg/m2 fludarabine; 12 pa-
tients received treosulfan 42 gm/m2, fludarabine 150 mg/m2, and 2






(n54) N(%) p value
Median age in
years (range)
31.6 (12.9-63.3) 33.3 (12.9-63.3) 24.9 (17.7-56.3) 0.76
Gender 0.93
Female 15 (52) 10 (47) 2 (50)
Male 14 (48) 11 (53) 2 (50)
HLA disparity* 0.20
4/6 19 (66) 14 (67) 1 (25)
5/6 8 (27) 6 (29) 2 (50)
6/6 2 (7) 1 (4) 1 (25)
CMV serostatus 0.65
Positive 18 (62) 13 (62) 2 (50)
Negative 11 (38) 8 (38) 2 (50)
Transplant type 0.50
Flu+Cy+TBI (13.2 Gy) 17 (81) 12 (57) 3 (75)
Flu+Treosulfan 12 (19) 9 (43) 1 (25)
GVHD prophylaxis CSA+MMF - - -
Median weight
in Kg (range)
76.1 (45.5-114.4) 76.1 (47.7-114.4) 72.2 (66-78.4) 0.57
Disease 0.96
AML 14 (48) 11 (52) 2 (50)
ALL 8 (28) 5 (24) 1 (25)
CML 2 (7) 1 (5) -
MDS/MPD 4 (14) 3 (14) 1 (25)
CLL 1 (3) 1 (5) -
Median TNC infused**
x107/Kg (range)
3.5 (1.8-6.4) 3.3 (2.3-6.4) 3.3 (2.6-4.0) 0.61
Median CD34 infused**
x106/Kg (range)
0.16 (0.08-0.66) 0.14 (0.08-0.66) 0.26 (0.20-0.31) 0.23
Median CD3 infused***
x106/Kg (range)
10.7 (6.9-18.5) 10.8 (6.9-18.5) 10.4 (9.4-16.4) 0.92
Viability*** % (range) 75 (60-87) 74 (60-87) 78 (72-79) 0.33
*For dCBT, HLA disparity reflects the lower match of the 2 units.
**Post thaw.
***Post wash.dian infused cell doses were: 3.5  107 TNC/kg, 0.16  106 CD34/
kg, and 10.7  106 CD3/kg. Day 7 CD3 chimerisms were evaluable
in 25/29 patients. We found no correlation between engrafting unit
and infused TNC, CD34, or CD3 dose, nor unit viability or HLA
disparity. In 21/25 patients (Group A), the unit with higher CD3 chi-
merism on day 7 became the engrafting unit [OR 27.5 (95%CI: 6.0-
125.0), p 5 0.0001]. Furthermore, the mean day 7 CD3 chimerism
was significantly different between the winning and losing units in
this group (p\ 0.0001). CD3 chimerism from the non-engrafting
unit was higher at day 7 in only 4 patients (Group B).
Conclusions: Donor day 7 CD3 peripheral blood chimerism is
highly predictive of the long-term engrafting unit in the setting of
myeloablative dCBT. These results further support the hypothesis
that single-donor dominance is immune-mediated by graft-graft in-
teractions, andmay provide insight into basic principles of transplant
immunology. Importantly, the ability to predict the long-term en-
grafting unit at day 7 would allow for early selection of the cord
blood unit to be used for adoptive immunotherapy post transplant.55
SCORING HLA MISMATCHES BY HistoCheck DOES NOT PREDICT
CLINICAL OUTCOME IN HCT
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High resolution HLA matching at HLA-A, B, C and DRB1 has
proven critical for optimal outcomes following unrelated donor
(URD) hematopoietic stem cell transplantation (HCT). Approxi-
mately 30% of URD HCT facilitated through by the National Mar-
row Donor Program (NMDP) are mismatched (MM) at one or more
loci. Currently, no rating system exists to reliably predict which HLA
MM URD should be selected for patients who do not have an HLA
allele matched donor. In 2002, Elsner and Blasczyk suggested that
a rating system, HistoCheck, might be used to identify acceptable
MM. This algorithm is based on the functional similarity of amino
acids weighted based on the position of the disparity in the HLAmol-
ecule to yield a Dissimilarity Score (DSS).
We evaluated the ability of DSS to predict the risk associated with
HLA disparity in a population of 744 single allele or antigen HLA-
A, B, or C MM myeloablative URD HCT for AML, ALL, CML or
MDS facilitated through the NMDP from 1988-2003. All pairs in
the study were retrospectively high resolution typed for HLA-A, B,
C, DRB1, DQB1 and DPB1. Multivariate models were used to adjust
for other significant clinical risk factors. A threshold of p\ 0.01 was
used to define significance due to multiple comparisons. HLA MM
were scored using the HistoCheck web-based tool and the patients
divided into 4 quartiles: DSS 1.04-2.84 (alleleMM), 2.84-13.75 (allele
and antigen MM), 13.75-19.385 (antigen MM) and 10.385-36.62
(antigen MM). Using the lowest scoring quartile as the reference, the
DSS groups were evaluated for an association with relapse, transplant
related mortality (TRM), acute and chronic GVHD, leukemia free
survival (LFS), and overall survival in the entire cohort and in subset
analyses by disease and disease stage.
No significant associations were found between DSS and any out-
comes in the overall cohort using the quartile categories or treating
DSS as a continuous variable. Higher DSS scores were associated with
decreased engraftment in early stage disease (p 5 0.0003) but not in
other disease stages. In disease subset analyses,DSS scorewas associated
with TRM, LFS and OS inMDS. However, theMDS subgroups were
very small (n5 10-21) diminishing confidence in the association.
In summary, DSS does not correlate with transplant outcome, and
theHistoCheck scoring system does not provide an effective strategy
to rank HLAMM. The dataset used in this study is available to eval-
uate new algorithms developed for donor selection.
